Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Multiple Sclerosis

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1352458516650992PMID 27246142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• European Committee for Treatment and Research in Multiple Sclerosis

  2019influential reference
• B2 Cell-based assays of CAG repeat instability in the huntingtin (HTT) gene

  2016cited by this paper
• Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis

  2015cited by this paper
• Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies

  2014cited by this paper
• Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study.

  2013cited by this paper
• Late effects of high‐dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging

  2012cited by this paper
• Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy

  2012cited by this paper
• Hematopoietic SCT for the treatment of multiple sclerosis

  2010cited by this paper
• Evidence for acute neurotoxicity after chemotherapy

  2010cited by this paper
• Wallerian Degeneration: A Major Component of Early Axonal Pathology in Multiple Sclerosis

  2010cited by this paper
• Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

  2010cited by this paper
• Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study

  2010cited by this paper
• The relation between inflammation and neurodegeneration in multiple sclerosis brains

  2009cited by this paper
• Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis.

  2009cited by this paper
• Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy.

  2008cited by this paper
• A Primer in Longitudinal Data Analysis

  2008cited by this paper
• Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system

  2008cited by this paper
• Why is Wallerian degeneration in the CNS so slow?

  2007cited by this paper
• A Three-Year Study of Brain Atrophy after Autologous Hematopoietic Stem Cell Transplantation in Rapidly Evolving Secondary Progressive Multiple Sclerosis

  2007cited by this paper
• Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy

  2007cited by this paper
• The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study

  2007cited by this paper
• Imaging correlates of axonal swelling in chronic multiple sclerosis brains

  2007cited by this paper
• CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo

  2006cited by this paper
• Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis

  2006cited by this paper
• Cortical demyelination and diffuse white matter injury in multiple sclerosis.

  2005cited by this paper
• Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation

  2004cited by this paper
• A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging.

  2003cited by this paper
• Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis

  2002cited by this paper
• Mixed-Effects Models in S and S-PLUS

  2001cited by this paper
• Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI

  2000cited by this paper
• Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis

  2000cited by this paper
• Progressive cerebral atrophy in MS

  2000cited by this paper
• Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability

  1999cited by this paper
• Imaging axonal damage of normal-appearing white matter in multiple sclerosis.

  1998cited by this paper
• Axonal transection in the lesions of multiple sclerosis.

  1998cited by this paper
• Axonal damage in acute multiple sclerosis lesions.

  1997cited by this paper
• Pharmacology of agents used in bone marrow transplant conditioning regimens.

  1992cited by this paper

• Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT

  2025cites this paper
• Longitudinal clinical and imaging analysis of hydrocephalus in a single-center study in 57 patients with mucopolysaccharidosis type IH (Hurler syndrome).

  2025cites this paper
• Longitudinal volumetric analysis of gray matter atrophy in metachromatic leukodystrophy

  2024cites this paper
• The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablative to myeloablative conditioning protocols.

  2024cites this paper
• Neuropsychological outcomes following HSCT in MS: A systematic review.

  2024cites this paper
• Brain volume increase after discontinuing natalizumab therapy: Evidence for reversible pseudoatrophy.

  2023cites this paper
• Understanding the Pathophysiology and Magnetic Resonance Imaging of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

  2023cites this paper
• Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation.

  2023cites this paper
• MRI graph parameters are longitudinal markers of neuronal integrity in multiple sclerosis.

  2023cites this paper
• Neurodegenerative disease after hematopoietic stem cell transplantation in metachromatic leukodystrophy

  2023cites this paper
• Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging

  2023cites this paper
• Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets

  2022cites this paper
• Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature

  2022cites this paper
• Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization

  2021cites this paper
• Early Aggressive Treatment Approaches for Multiple Sclerosis

  2021cites this paper
• Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis

  2021cites this paper
• Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis

  2020influential citation
• Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis

  2020cites this paper
• Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis

  2020cites this paper
• Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status

  2020cites this paper
• Improving longitudinal spinal cord atrophy measurements for clinical trials in multiple sclerosis by using the generalised boundary shift integral (GBSI)

  2020cites this paper
• Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation

  2019cites this paper
• Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS

  2019cites this paper
• HIV Eradication Strategies: Implications for the Central Nervous System

  2019cites this paper
• Therapeutic Advances in Neurological Disorders

  2019cites this paper
• Modulating inflammation and neuroprotection in multiple sclerosis

  2018cites this paper
• Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis

  2018cites this paper
• Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis

  2018cites this paper
• Stem Cell Therapy for Multiple Sclerosis.

  2018cites this paper
• Autologous haematopoietic stem cell transplantation for neurological diseases

  2017cites this paper
• A clinical and electrophysiological study of the effects of 4-aminopyridine on upper limb impairment in multiple sclerosis

  2017cites this paper
• Cell-based therapeutic strategies for multiple sclerosis

  2017cites this paper
• Imaging outcome measures for progressive multiple sclerosis trials

  2017cites this paper
• High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS

  2017cites this paper
• Targets of therapy in progressive MS

  2017cites this paper
• The future of multiple sclerosis treatments

  2016cites this paper
• Longitudinal change in Paced Auditory Serial Addition Test (PASAT) performance following immunoablative therapy and haematopoietic stem cell transplant in multiple sclerosis

  2016cites this paper
• The future of MS Treatments

  2016cites this paper